Study how corneal cell genetics relate to Fuchs’ disease
Part of Eyes & vision, Genetic & congenital clinical trials.
This study looks at how a person’s corneal cell genetic makeup relates to what happens in Fuchs’ corneal endothelial dystrophy. It may help doctors understand the disease better and guide future care, especially if you need a corneal transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are covered by the French social security system (or entitled to it)
- You are able to sign a consent form to join the study
- An eye specialist has diagnosed Fuchs’ corneal endothelial dystrophy using a slit-lamp exam
- Your care plan includes needing an endothelial corneal transplant (endothelial keratoplasty)
- You are not under legal guardianship or court-appointed curatorship
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy to treat a type of corneal dystrophy caused by a faulty gene. It aims to improve symptoms and slow the disease's progression.
This trial tests a surgical technique called Descemet membrane polishing during corneal transplant surgery for Fuchs endothelial corneal dystrophy, a condition that clouds the cornea (the clear front part of your eye). The study aims to see if this polishing step improves healing and vision after surgery.
This study follows people with Fuchs' endothelial corneal dystrophy over time to see how the condition changes and how it relates to their genes. It aims to help doctors better predict and manage the disease.
This study tests a scoring system to predict how well people with Fuchs dystrophy do after cataract surgery. It may help doctors plan better treatment for your cornea and lens.
This trial tests an investigational eye drop (DT-168) in people with Fuchs endothelial corneal dystrophy who are already scheduled for a corneal transplant. The goal is to see if DT-168 can improve outcomes or delay the need for surgery.
This Phase 3 trial compares outcomes from two cornea transplant procedures in people with FECD, a disease that makes the cornea swell and affect vision. It may help you and others by identifying which approach best supports clear vision and stable corneal thickness after surgery.
Hear when a new Corneal Dystrophies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.